Fabhalta, Empaveli affect blood proteins differently in C3G, study finds

Tracking these changes may help doctors better monitor treatment effects

Written by Michela Luciano, PhD |

A lab technician holds up a fluid-filled test tube, with several test tubes in the background.

Fabhalta and Empaveli, two approved treatments for C3 glomerulopathy, cause different changes in blood proteins that may help doctors monitor treatment effects, a study found. (Photo from iStock)

Fabhalta (iptacopan) and Empaveli (pegcetacoplan), two approved treatments for C3 glomerulopathy (C3G), cause different changes in blood proteins that may help doctors monitor treatment effects, a U.S. study found.

While both treatments suppressed activity in the alternative pathway of the complement cascade, a part of the immune system that is overactive in C3G, they affected blood levels of complement proteins differently, reflecting how each drug works.

Most of the 18 patients included in the study showed the expected protein changes, although some had persistent abnormalities suggesting that parts of the complement system might remain overactive despite treatment.

“Pathway-based biomarker assessment may distinguish expected treatment effects from incomplete or discordant biochemical control,” researchers wrote. Still, they emphasized that “these categories describe [biomarker] patterns rather than clinical efficacy and require validation against clinical outcomes.”

The study, “Distinct Pharmacodynamic Complement Biomarker Signatures Define Iptacopan and Pegcetacoplan Treatment in C3 Glomerulopathy,” was published in Kidney International Reports.

Recommended Reading
A hand holding a blue marker next to a yellow sticky note labeled “Clinical Trials,” with a stethoscope in the background.

Experimental C3G therapy may reduce protein in urine, early data suggest

Drugs act at different steps

In C3G, excessive activity of the alternative pathway of the complement cascade causes C3, a complement protein, to break down into fragments. These fragments build up in the kidneys, leading to inflammation and damage to the kidneys’ filtering units.

Fabhalta, taken orally twice daily, blocks factor B, a protein that helps amplify alternative pathway activity and promote C3 breakdown. Empaveli, injected under the skin twice weekly, targets C3 and its activated form, C3b, preventing further complement activation.

Because the drugs act at different steps, they are expected to affect blood levels of complement proteins and their breakdown products differently. This means that, when monitoring treatment effects, individual blood biomarkers should not be interpreted on their own, but rather according to how each treatment works.

A team of researchers in the U.S. therefore sought to identify treatment-specific patterns of blood biomarker changes and develop a way to classify patients based on how closely their blood test results matched the expected patterns.

Treatments’ effects on individual proteins differed considerably

They analyzed blood samples from 18 people with C3G enrolled in a natural history study between July 2022 and June 2025. Half were treated with Fabhalta, while the other half received Empaveli. Samples were collected before treatment and approximately three months afterward.

The team assessed blood C3 levels, alternative pathway activity and factor B breakdown, activation of the final steps of the complement cascade, and overall complement pathway function.

Both treatments strongly suppressed alternative pathway activity and reduced sC5b-9, a marker of the final steps of complement cascade activation, suggesting that both drugs were acting as designed. However, their effects on individual proteins, particularly C3, differed considerably.

With Fabhalta, mean blood C3 levels rose from 38.2 mg/dL to 103.4 mg/dL, returning to the normal range, and indicating that there was less C3 breakdown. Levels of factor B and two other complement proteins, C5 and properdin, also increased, while levels of C3a and C3d, two fragments produced from C3 breakdown, declined. These changes were consistent with reduced complement activation and consumption of complement proteins.

Empaveli produced a much larger increase in C3, with mean levels rising from 37.9 mg/dL to 287.3 mg/dL, well above the normal range. Levels of C3c, another C3 fragment, and properdin also increased, while C3a, C3d, and Bb, a breakdown product of factor B, declined. The researchers noted that unusually high C3 levels are expected with Empaveli and do not necessarily indicate uncontrolled complement activity.

Most patients in each treatment group showed the expected changes

Another difference involved CH50, a test measuring activity of another complement pathway called the classical pathway. CH50 increased with Fabhalta, indicating “improved functional activity of the classical complement pathway,” the team wrote. In contrast, CH50 was generally maintained or increased with Empaveli.

The researchers then classified patients’ overall blood biomarker patterns into three categories based on how closely they matched the expected effects of each treatment. Six of nine patients (66.7%) in each treatment group showed the expected changes. Another three receiving Fabhalta (33.3%) and two receiving Empaveli (22.2%) showed largely expected patterns, but some abnormalities persisted.

[Fabhalta and Empaveli] suppress complement activation in C3G but generate distinct … biomarker signatures.

One Empaveli-treated patient (11.1%) showed more substantial abnormalities. This patient had a severe deficiency of factor H, a protein that helps regulate complement activity. Although C3 and several other markers improved, factor B remained unusually low and its breakdown products elevated, suggesting continued factor B consumption. These abnormalities persisted after a kidney transplant and a subsequent switch to Fabhalta.

Fabhalta and Empaveli “suppress complement activation in C3G but generate distinct … biomarker signatures,” the researchers concluded. They added that “a mechanism-informed, pathway-based approach incorporating” different complement biomarkers together “may help distinguish expected treatment-specific effects from incomplete or discordant biochemical pathway control.”

However, the researchers stressed that further studies are needed to determine whether these patterns of blood biomarker changes can predict treatment responses, disease recurrence, or long-term kidney outcomes, or help identify patients who might benefit from switching treatments.